Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure

American Journal of Cardiology

Volumn 95, Issue 9 SUPPL. 1, 2005, Pages 14-23

  Goldsmith, Steven R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; CAPTOPRIL; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CONIVAPTAN; DEMECLOCYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LITHIUM CARBONATE; LIXIVAPTAN; LOOP DIURETIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; POTASSIUM SPARING DIURETIC AGENT; SODIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UREA; VASOPRESSIN ANTAGONIST;

ARTERIAL PRESSURE; BRAIN EDEMA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FLUID INTAKE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART OUTPUT; HEART PRELOAD; HUMAN; HYPONATREMIA; HYPOTENSION; KIDNEY DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; POLYURIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THIRST; URINARY FREQUENCY; VASCULAR RESISTANCE; WATER RETENTION; XEROSTOMIA;

EID: 17444400790     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.03.004     Document Type: Article

References (40)

1. M. Thibonnier Vasopressin receptor antagonists in heart failure Curr Opin Pharmacol 3 2003 683 687
2. A. Greenberg Diuretic complications Am J Med Sci 319 2000 10 24
3. R.H. Sterns, J.D. Cappuccio, S.M. Silver, E.P. Cohen Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective J Am Soc Nephrol 4 1994 1522 1530
4. R.H. Sterns, J.E. Riggs, S.S. Schochet Osmotic demyelination syndrome following correction of hyponatremia N Engl J Med 314 1986 1535 1542
5. R.H. Sterns Severe symptomatic hyponatremia: treatment and outcome Ann Intern Med 107 1987 656 664
6. R.H. Sterns The treatment of hyponatremia: first, do no harm Am J Med 88 1990 557 560
7. C.L. Fraser, A.I. Arieff Epidemiology, pathophysiology, and management of hyponatremic encephalopathy Am J Med 102 1997 67 77
8. H.J. Adrogué, N.E. Madias Hyponatremia N Engl J Med 342 2000 1581 1589
9. K.P. Goh Management of hyponatremia Am Fam Physician 69 2004 2387 2394
10. D.H. Ellison, R.W. Schrier The edematous patient: cardiac failure, cirrhosis, and nephrotic syndrome In: Schrier RW, ed. Manual of Nephrology 2000 Lippincott Williams & Wilkins Philadelphia 1-36
11. P.J. Fall Hyponatremia and hypernatremia: a systematic approach to causes and their correction Postgrad Med 107 2000 75 82
12. S.R. Gullans, J.F. Verbalis Control of brain volume during hyperosmolar and hypoosmolar conditions Ann Rev Med 44 1993 289 301
13. J.G. Verbalis, S.R. Gullans Hyponatremia causes large sustained reductions in brain content of multiple organic osmolytes in rats Brain Res 567 1991 274 282
14. J.G. Verbalis Adaptation to acute and chronic hyponatremia: implications for symptomatology, diagnosis, and therapy Semin Nephrol 18 1998 3 19
15. S. Kumar, T. Berl Diseases of water metabolism R.W. Schrier Atlas of Diseases of the Kidney 1999 Current Medicine Inc. Philadelphia 1.1 1.21
16. J.C. Ayus, A.I. Arieff Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality JAMA 281 1999 2299 2304
17. C. Brater Diuretic therapy in congestive heart failure Congestive Heart Fail 6 2000 197 201
18. M. Packer, W.H. Lee, P.D. Kessler, N. Medin, M. Yushak, S.S. Gottlieb Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure J Am Coll Cardiol 10 1987 837 844
19. N. Janicic, J.G. Verbalis Evaluation and management of hypo-osmolality in hospitalized patients Endocrinol Metab Clin North Am 32 2003 459 481
20. J.G. Verbalis The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders R.W. Schrier Diseases of the Kidney 1996 Brown & Co. Boston: Little 2393 2427
21. G. Licata, P. Di Pasquale, G. Parrinello, A. Cardinale, A. Scandurra, G. Follone, C. Argano, A. Tuttolomondo, S. Paterna Effects.of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in.refractory congestive heart failure: long-term effects Am Heart J 145 2003 459 466
22. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 292 2000 288 294
23. E.K. Jackson Diuretics J.G. Hardman L.E. Limbird Goodman and Gilman's the Pharmacological Basis of Therapeutics 9th ed 1996:757-788 McGraw-Hill New York
24. P.D. Miller, S.L. Linas, R.W. Schrier Plasma demeclocycline levels and nephrotoxicity: correlation in hyponatremic cirrhotic patients JAMA 243 1980 2513 2515
25. A. Tahara, M. Saito, J. Tsukada, N. Ishii, Y. Tomura, K. Wada, T. Kusayama, T. Yatsu, W. Uchida, A. Tanaka Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells Eur J Pharmacol 368 1999 89 94
26. 1b receptors Pflugers Arch 437 1999 219 226
27. C.R. Lee, M.L. Watkins, J.H. Patterson, W. Gattis, C.M. O'Connor, M. Gheorghiade, K.F. Adams Jr Vasopressin: a new target for the treatment of heart failure Am Heart J 146 2003 9 18
28. M.J. Clair, M.K. King, A.T. Goldberg, J.W. Hendrick, R. Nisato, D.M. Gay, A.E. Morrison, J.H. McElmurray III, R.S. Krombach, and B.R. Bond Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure J Pharmacol Exp Ther 293 2000 852 860
29. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, for the Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-2696.
30. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vaspressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971.
31. F. Wong, A.T. Blei, L.M. Blendis, P.J. Thuluvath A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial Hepatology 37 2003 182 191
32. A.L. Gerbes, V. Gulberg, P. Gines, G. Decaux, P. Gross, H. Gandjini, J. Djian VPA Study Group Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial Gastroenterology 124 2003 933 939
33. 2 receptor blockade and ACE inhibition Cardiovasc Res 54 2002 51 57
34. 2 receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs Pharmacol Res 46 2002 375 381
35. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure Eur J Pharmacol 376 1999 239 246
36. 2 receptor antagonist, in vitro and in vivo J Pharmacol Exp Ther 282 1997 301 308
37. 2 receptor antagonist, in dogs Eur J Pharmacol 321 1997 225 230
38. A. Tahara, Y. Tomura, K. Wada, T. Kusayama, J. Tsukada, N. Ishii, T. Yatsu, W. Uchida, A. Tanaka Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte Cardiovasc Res 38 1998 198 205
39. 2 vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2001 2417 2423
40. S.D. Russell, P. Selaru, D.A. Pyne, M.M Ghazzi, K.D Massey, M. Pressler, A. Serikoff, A.J. Coats Rationale for use of an exercise end point and design for the ADVANCE (A Dose Evaluation of a Vasopressin Antagonist in CHF Patients Undergoing Exercise) trial Am Heart J 145 2003 179 186